Milciclib is under clinical development by Tiziana Life Sciences and currently in Phase I for Colon Cancer. According to GlobalData, Phase I drugs for Colon Cancer have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Milciclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Milciclib overview

Milciclib (PHA-848125) is under development for the treatment of thymoma, metastatic hepatic cellular carcinoma (HCC), thyroid cancer, prostate cancer, solid tumors including non small cell lung cancer, pancreatic and colon cancer and thymic carcinoma. It is administered orally in the form of the capsule. It is developed based on kinase platform technology. The drug candidate acts by targeting cyclin-dependent kinase-1 (CDK-1), cyclin-dependent kinase-2 (CDK-2), cyclin-dependent kinase-4 (CDK-4), cyclin-dependent kinase-5 (CDK-5), cyclin-dependent kinase-7 (CDK-7), pan src family kinases  and tropomyosin receptor kinase A (TRKA). The drug candidate was also under development for recurrent malignant glioma and malignant pleural mesothelioma.

Tiziana Life Sciences overview

Tiziana Life Sciences Ltd (Tiziana), formerly Tiziana Life Sciences, is a clinical-stage biotechnology company that discovers and develops drugs to treat inflammatory diseases and cancers. Its lead product candidate, Milciclib (TZLS-201), intended for the treatment of thymic carcinoma. The company’s other clinical programs includes Foralumab (TZLS-401), a human engineered anti-human CD3 antibody intended for the treatment of Crohn’s disease and Nonalcoholic steatohepatitis. The company’s preclinical stage candidates include anti-IL6R (TZLS-501), a fully human anti-IL-6R monoclonal antibody targeting the interleukin-6 receptor. Tiziana is headquartered in Hamilton, Bermuda, the UK.

For a complete picture of Milciclib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.